Thiopurines and myeloid disorders: is more caution needed when treating inflammatory bowel disease patients?

References

• Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465-83
   PubMed Web of Science ®Google Scholar
• Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28-62
   PubMed Web of Science ®Google Scholar
• Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American College Of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2010;105:501-23
   PubMed Web of Science ®Google Scholar
• Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Oussalah A, Williet N, et al. Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn’s disease. Gut 2011;60:930-6
   PubMed Web of Science ®Google Scholar
• Williet N, Pillot C, Oussalah A, et al. Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics. Inflamm Bowel Dis 2012;18:1641-6
   PubMed Web of Science ®Google Scholar
• Sahasranaman S, Howard D, Roy S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753-67
   PubMed Web of Science ®Google Scholar
• Bean RH. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust 1962;49:592-3
   PubMed Web of Science ®Google Scholar
• Jess T, Lopez A, Andersson M, et al. Thiopurines and risk of colorectal neoplasia in patients with inflammatory bowel disease: a meta-analysis. Clin Gastroenterol Hepatol 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-8
   PubMed Web of Science ®Google Scholar
• Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14
   PubMed Web of Science ®Google Scholar
• Morton LM, Gibson TM, Clarke CA, et al. Risk of myeloid neoplasms after solid organ transplantation. Leukemia 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Lopez A, Mounier M, Bouvier AM, et al. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease. Clin Gastroenterol Hepatol 2014;12:1324-9
   PubMed Web of Science ®Google Scholar
• Kappelman MD, Farkas DK, Long MD, et al. Risk of cancer in patients with inflammatory bowel diseases: a nationwide population-based cohort study with 30 years of follow-up evaluation. Clin Gastroenterol Hepatol 2014;12:265-73
   PubMed Web of Science ®Google Scholar
• Fabry TL, Sachar DB, Janowitz HD. Acute myelogenous leukemia in patients with ulcerative colitis. J Clin Gastroenterol 1980;2:225-7
   PubMed Web of Science ®Google Scholar
• Greenstein AJ, Gennuso R, Sachar DB, et al. Extraintestinal cancers in inflammatory bowel disease. Cancer 1985;56:2914-21
   PubMed Web of Science ®Google Scholar
• Mir Madjlessi SH, Farmer RG, Weick JK. Inflammatory bowel disease and leukemia. A report of seven cases of leukemia in ulcerative colitis and Crohn’s disease and review of the literature. Dig Dis Sci 1986;31:1025-31
   PubMed Web of Science ®Google Scholar
• Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005;54:617-22
   PubMed Web of Science ®Google Scholar
• Anderson LA, Pfeiffer RM, Landgren O, et al. Risks of myeloid malignancies in patients with autoimmune conditions. Br J Cancer 2009;100:822-8
   PubMed Web of Science ®Google Scholar
• Korelitz BI, Mirsky FJ, Fleisher MR, et al. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53
   PubMed Web of Science ®Google Scholar
• Harewood GC, Loftus EV Jr, Tefferi A, et al. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflammatory bowel diseases. Inflamm Bowel Dis 1999;5:98-103
   PubMed Web of Science ®Google Scholar
• Kristinsson SY, Bjorkholm M, Hultcrantz M, et al. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes. J Clin Oncol 2011;29:2897-903
   PubMed Web of Science ®Google Scholar
• Smith M, Blaker P, Patel C, et al. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract 2013;67:161-9
   PubMed Web of Science ®Google Scholar
• Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study. Blood 2009;113:6077-84
   PubMed Web of Science ®Google Scholar
• Panes J, Lopez-Sanroman A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology 2013;145:766-74
   PubMed Web of Science ®Google Scholar